Table 7.
In vitro inhibition of cancer cell lines growth in leukaemia, colon, renal, and breast cancer subpanels by compounds 2t–w, 2z, 2ab, 2ae, and 2ak–am.
| Cell Line | GI50 (µM) a | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2t | 2u | 2v | 2w | 2z | 2ab | 2ae | 2ak | 2al | 2am | |
| Leukaemia | ||||||||||
| CCRF-CEM | 2.76 | 1.94 | 2.12 | 2.25 | 2.12 | 1.83 | 3.07 | 0.45 | 1.97 | 1.73 |
| HL-60(TB) | 2.11 | 1.88 | 1.77 | 1.86 | 1.93 | 1.72 | 2.52 | 1.67 | 1.80 | 1.70 |
| K-562 | 2.08 | 1.74 | 1.72 | 1.88 | 1.95 | 1.61 | 2.94 | 0.24 | 1.49 | 1.49 |
| MOLT-4 | 1.85 | 1.82 | 1.83 | 1.80 | 1.86 | 1.77 | 1.79 | 0.60 | 1.79 | 1.54 |
| RPMI82226 | 1.92 | 2.08 | 2.04 | 2.19 | 1.99 | 1.84 | 1.68 | 0.77 | 1.84 | 1.89 |
| SR | 2.30 | 1.89 | 2.05 | 1.84 | 2.01 | 1.68 | 2.29 | 0.27 | 1.70 | 1.58 |
| Colon Cancer | ||||||||||
| COLO-205 | 1.82 | 1.67 | 1.73 | 1.80 | 1.85 | 1.73 | 2.09 | 1.49 | 1.78 | 1.63 |
| HCC-2998 | 2.04 | 1.71 | 1.70 | 1.78 | 1.91 | 1.74 | 3.42 | 1.47 | 1.59 | 1.86 |
| HCT-116 | 1.85 | 1.70 | 1.75 | 1.68 | 1.78 | 1.60 | 3.00 | 0.28 | 1.83 | 1.37 |
| HCT-15 | 2.32 | 1.72 | 1.73 | 1.57 | 1.96 | 1.58 | 2.28 | 0.24 | 1.70 | 1.45 |
| HT29 | 2.22 | 1.75 | 1.68 | 1.81 | 2.18 | 1.56 | 2.85 | 0.31 | 1.70 | 1.59 |
| KM12 | 2.41 | 1.61 | 1.77 | 1.87 | 1.93 | 1.73 | 2.85 | 1.09 | 1.69 | 1.70 |
| SW-620 | 2.26 | 1.82 | 1.92 | 2.00 | 1.99 | 1.74 | 3.62 | 0.31 | 1.83 | 1.62 |
| Renal Cancer | ||||||||||
| 786-0 | 1.74 | 1.63 | 1.65 | 1.61 | 1.78 | 1.59 | 2.91 | 0.42 | 1.65 | 1.61 |
| A498 | 0.48 | 1.83 | 2.57 | 1.82 | 0.22 | 1.43 | 5.66 | 0.02 | 1.60 | 1.66 |
| ACHN | 2.50 | 1.66 | 1.70 | 1.62 | 1.79 | 1.66 | 2.82 | 1.50 | 1.73 | 165 |
| CAKI-1 | 1.88 | ND b | ND b | ND b | 1.80 | ND b | ND b | 1.39 | ND b | ND b |
| RXF 393 | 2.09 | 1.62 | 1.61 | 1.59 | 1.73 | 1.38 | 2.58 | 0.93 | 1.52 | 1.33 |
| SN12C | 3.16 | 1.68 | 1.74 | 1.75 | 1.91 | 1.60 | 3.15 | 6.05 | 1.53 | 1.61 |
| TK-10 | 3.48 | 2.22 | 1.85 | 1.59 | 5.25 | 1.51 | 3.28 | 4.25 | 1.58 | 1.53 |
| UO-31 | 1.37 | 1.18 | 1.28 | 1.38 | 1.43 | 1.38 | 2.20 | 1.11 | 1.46 | 1.43 |
| Breast Cancer | ||||||||||
| MCF-7 | 1.43 | 1.24 | 1.53 | 1.43 | 1.56 | 1.53 | 1.94 | 1.65 | 1.62 | 1.70 |
| MDA-MB-231/ATCC | 1.86 | 1.63 | 1.69 | 1.66 | 1.70 | 1.61 | 2.51 | 0.52 | 1.64 | 1.64 |
| HS 578T | 2.08 | 2.34 | 2.59 | 2.05 | 2.05 | 1.66 | 3.75 | 0.76 | 12.40 | 1.50 |
| BT-549 | 2.00 | 1.68 | 3.72 | 3.28 | 3.74 | 1.66 | 2.17 | 2.97 | 1.67 | 1.64 |
| T-47D | 2.07 | 1.22 | 1.77 | 1.75 | 2.12 | 1.45 | 1.52 | 12.0 | 15.70 | 1.65 |
| MDA-MB-468 | 2.52 | 1.88 | 1.61 | 1.86 | 1.95 | 1.68 | 2.20 | 0.97 | 1.51 | 1.50 |
a Concentration (µM) that inhibits 50% net cell growth. b ND = Not Determined.